* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions),
depending on your out-of-pocket costs. Not valid for patients participating in Medicare,
Medicaid, government (public insurance) programs, or any private payor in the state
of Massachusetts and where prohibited by law.
AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties
with sleep onset and/or sleep maintenance. AMBIEN CR is not indicated for the treatment
of GAD or MDD.
Due to its rapid onset of action, patients should take AMBIEN CR right before going
to bed and when ready for sleep.
IMPORTANT SAFETY INFORMATION
Patients should not take AMBIEN CR unless they are prepared to get a full night’s
sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect
their physical or mental performance upon awakening, patients should not drive or
operate hazardous machinery after taking AMBIEN CR or any other sleep medication.
Complex behaviors such as somnambulism, including driving or eating while not fully
awake, with amnesia for the event, as well as abnormal behaviors such as being more
outgoing or aggressive than normal, confusion, agitation, and hallucinations may
occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal
behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients
reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN
CR and in rare cases may be fatal. Patients who develop angioedema should not be
rechallenged. In primarily depressed patients, worsening of depression, including
risk of suicidal thoughts or actions, including completed suicides, have been reported.
Therefore, AMBIEN CR should be administered with caution to patients exhibiting
signs or symptoms of depression, in whom suicidal tendencies may be present and
protective measures may be required. Intentional overdosage is more common in this
group of patients; the least amount of drug that is feasible should be prescribed
for the patient at any one time.The most commonly observed adverse events in controlled
clinical trials were headache, somnolence, and dizziness.
Please refer to the full prescribing information.